PL03.08. First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-Mutant NSCLC: DESTINY-Lung04 Primary Results

Monday, September 14, 2026 10:10 AM to 10:20 AM · 10 min. (Asia/Seoul)

Join the event!

See all the content and easy-to-use features by logging in or registering!